ATE213152T1 - Verbesserte arzneimittel mit einem ionenaustauschharz - Google Patents

Verbesserte arzneimittel mit einem ionenaustauschharz

Info

Publication number
ATE213152T1
ATE213152T1 AT96928628T AT96928628T ATE213152T1 AT E213152 T1 ATE213152 T1 AT E213152T1 AT 96928628 T AT96928628 T AT 96928628T AT 96928628 T AT96928628 T AT 96928628T AT E213152 T1 ATE213152 T1 AT E213152T1
Authority
AT
Austria
Prior art keywords
ion exchange
exchange resin
pct
date
sugar
Prior art date
Application number
AT96928628T
Other languages
English (en)
Inventor
Sandra Therese Antoi Malkowska
Derek Allan Prater
Stewart Thomas Leslie
Adrian Brown
Trevor John Knott
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE213152T1 publication Critical patent/ATE213152T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT96928628T 1995-09-01 1996-09-02 Verbesserte arzneimittel mit einem ionenaustauschharz ATE213152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9517883.6A GB9517883D0 (en) 1995-09-01 1995-09-01 Improved pharmaceutical ion exchange resin composition
PCT/GB1996/002156 WO1997009036A2 (en) 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition

Publications (1)

Publication Number Publication Date
ATE213152T1 true ATE213152T1 (de) 2002-02-15

Family

ID=10780065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928628T ATE213152T1 (de) 1995-09-01 1996-09-02 Verbesserte arzneimittel mit einem ionenaustauschharz

Country Status (9)

Country Link
US (1) US6077532A (de)
EP (1) EP0847273B1 (de)
AT (1) ATE213152T1 (de)
AU (1) AU6834796A (de)
DE (1) DE69619250T2 (de)
ES (1) ES2170258T3 (de)
GB (1) GB9517883D0 (de)
PT (1) PT847273E (de)
WO (1) WO1997009036A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288876A1 (en) * 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
EP1041988A4 (de) * 1997-12-22 2002-03-13 Euro Celtique Sa Verfahren zur vorbeugung von missbrauch von opioid-dosis-formen
EP1041987B1 (de) 1997-12-22 2006-04-19 Euro-Celtique S.A. Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6221308B1 (en) * 1999-04-20 2001-04-24 Corning Incorporated Method of making fired bodies
EP2092936B1 (de) 2000-02-08 2013-03-20 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CN1845722A (zh) * 2003-09-03 2006-10-11 马林克罗特公司 粒状缓释制剂及其生产
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
EP1834634A3 (de) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Aus mehrfacher Einzeleinheiten bestehender pharmazeutische Zusammensetzung
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
WO2024163966A1 (en) 2023-02-03 2024-08-08 Tris Pharma, Inc. Low sodium oxybate once nightly composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
EP0200252B1 (de) * 1985-05-02 1999-03-10 Yamanouchi Europe B.V. Trimethoprim und ein Sulfonamid enthaltende Tabletten
EP0328877A1 (de) * 1988-02-18 1989-08-23 Oerlikon-Contraves AG Geschoss mit Splittermantel
FI81004C (fi) * 1988-02-25 1990-09-10 Suomen Sokeri Oy Binde- och utspaedningsmedel pao basis av xylitol och foerfarande foer dess framstaellning.
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
HU206975B (en) * 1991-03-14 1993-03-01 Reanal Finomvegyszergyar Process for producing granulation and veterinary composition comprising water-soluble flumequine complex

Also Published As

Publication number Publication date
EP0847273B1 (de) 2002-02-13
DE69619250T2 (de) 2002-08-14
ES2170258T3 (es) 2002-08-01
PT847273E (pt) 2002-06-28
EP0847273A2 (de) 1998-06-17
US6077532A (en) 2000-06-20
WO1997009036A2 (en) 1997-03-13
WO1997009036A3 (en) 1997-04-24
GB9517883D0 (en) 1995-11-01
AU6834796A (en) 1997-03-27
DE69619250D1 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE213152T1 (de) Verbesserte arzneimittel mit einem ionenaustauschharz
AU5106996A (en) Process for producing active agent preparations in the form of a solid solution of the active agent in a polymer matrix and active agent preparations obtained thereby
NO971986D0 (no) Fremgangsmåte for fremstilling av små partikler
AU4453089A (en) Pharmaceutical ion exchange resin composition
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
AU6870396A (en) New pyrimidone derivatives with antifungal activity
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
ATE259815T1 (de) Neue antagonistische verbindungen
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
AU6518496A (en) Process for preparing optically active 1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline
GEP19991819B (en) Method for Production of Therapeutic Form of Carbamazepin with Retarded Active Substance Release
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
PT97541A (pt) Processo para a preparacao de indoles substituidos
BR9611572A (pt) Produção de um sal de ácido clavulânico
HUT74434A (en) Oral dosage form containing colestipol as a carrier and acidic substances and a process for producing the same
HK1016154A1 (en) Process for preparing 4-cyano-2,5-difluoroaniline

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification